Αποτελέσματα Αναζήτησης
3 Ιουν 2021 · In the OlympiA trial, we hypothesized that olaparib would provide benefit as an adjuvant therapy for patients with germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant–associated ...
10 Οκτ 2022 · Adjuvant olaparib versus placebo significantly improved OS in g BRCA1 /2pv-associated human epidermal growth factor receptor 2-negative EBC (4-year OS 90% versus 86%). Adjuvant olaparib versus placebo improved 4-year IDFS (83% versus 75%) and 4-year DDFS (87% versus 79%).
1 Φεβ 2024 · OlympiA, a randomized, double-blind, parallel group, placebo (PL)-controlled, multi-center phase III study, compared 1 year of olaparib (OL) with PL as adjuvant therapy in patients with germline pathogenic or likely pathogenic variants in BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2 (HER2)–negative early ...
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-ne...
12 Οκτ 2022 · With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in overall survival (OS) with adjuvant olaparib compared with placebo for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 and high-risk, HER2-negative early breast cancer. Adjuvant olaparib maintained improvements in ...
1 Δεκ 2022 · We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated.
16 Ιουν 2021 · OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Authors: Andrew Tutt, Judy Ellen Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, …
